Income investors shouldn't be too worried about the pharma giant cutting its dividend.

In August 2026, Pfizer and BioNTech received U.S. FDA approval for their updated COMIRNATY COVID-19 vaccine targeting the XFG variant for high-risk individuals, while Pfizer and Valneva’s Lyme disease ...

Pfizer has raised its dividend every year for over a decade, then something changed. Before you count on that 6% yield, find ...

Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage ...

Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves ...

The drugmaker has targeted air-traffic control fees in a dispute with Poland and Romania.

Pfizer has a huge 6% yield and a payout ratio well over 100%, yet the company is still maintaining the dividend.

When Pfizer was coming out of the COVID-induced growth phase in early 2024, I turned bullish alongside CEO Albert Bourla, effectively betting his pension on Pfizer stock. Since then, Pfizer has proven ...

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

It must have been a pretty good few months for Pfizer investors (PFE) as the stock surprisingly outperformed the S&P 500 (SPX) (SPY) during this period since I last updated PFE in May. In my previous ...

ast June, when AI drug discovery startup Chai Discovery was just 15 months old, it released a new model that could design antibodies. Nearly 20 pharma companies reached out to talk. “It was like we ...